Skip to Content
U.S. National Institutes of Health
Last Updated: 10/28/10


The Biological Resources Branch supports preclinical and early (e.g., Phase I) clinical studies of biological response modifiers through a program of grants and contracts. These studies assess the effects of novel biological agents and explore relationships of biological responses with antitumor activity. The Biological Resources Branch supports the NCI Preclinical Repository, which distributes selected agents for peer-reviewed preclinical studies performed by both extramural and intramural investigators. Program staff also oversees a multiproduct current Good Manufacturing Practices (cGMP) facility known as the Biopharmaceutical Development Program (BDP) at NCI-Frederick. The BDP produces a variety of cGMP-grade biopharmaceuticals for clinical trials or advanced preclinical animal testing.